Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;5(5):CD006961.
doi: 10.1002/14651858.CD006961.pub5.

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis

Sherie Smith  1 , Felix Ratjen  2 , Tracey Remmington  3 , Valerie Waters  4
Affiliations

Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis

Sherie Smith et al. Cochrane Database Syst Rev. .

Abstract

Background: Antibiotic therapy for acute pulmonary exacerbations in people with cystic fibrosis is usually chosen based on the results of antimicrobial susceptibility testing of individual drugs. Combination antimicrobial susceptibility testing assesses the efficacy of drug combinations including two or three antibiotics in vitro and can often demonstrate antimicrobial efficacy against bacterial isolates even when individual antibiotics have little or no effect. Therefore, choosing antibiotics based on combination antimicrobial susceptibility testing could potentially improve response to treatment in people with cystic fibrosis with acute exacerbations. This is an updated version of a previously published review.

Objectives: To compare antibiotic therapy based on conventional antimicrobial susceptibility testing to antibiotic therapy based on combination antimicrobial susceptibility testing in the treatment of acute pulmonary exacerbations in people with cystic fibrosis and chronic infection with Pseudomonas aeruginosa.

Search methods: We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Cystic Fibrosis Trials Register which comprises of references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. Date of latest search: 19 March 2020. We also searched ongoing trials registries. Date of latest search: 07 April 2020.

Selection criteria: Randomised and quasi-randomised controlled studies of antibiotic therapy based on conventional antimicrobial susceptibility testing compared to antibiotic therapy based on combination antimicrobial susceptibility testing in the treatment of acute pulmonary exacerbations in cystic fibrosis due to chronic infection with Pseudomonas aeruginosa.

Data collection and analysis: Both authors independently selected studies, assessed their quality and extracted data from eligible studies. Additionally, the authors contacted the study investigators to obtain further information.

Main results: The search identified one multicentre study eligible for inclusion in the review. This study prospectively assessed whether the use of multiple combination bactericidal antibiotic testing improved clinical outcomes in participants with acute pulmonary exacerbations of cystic fibrosis who were infected with multiresistant bacteria. A total of 132 participants were randomised in the study. The study investigators provided data specific to the 82 participants who were only infected with Pseudomonas aeruginosa for their primary outcome of time until next pulmonary exacerbation. For participants specifically infected with only Pseudomonas aeruginosa, the hazard ratio of a subsequent exacerbation was 0.82, favouring the control group (95% confidence interval 0.44 to 1.51) (P = 0.52). No further data for any of this review's outcomes specific to participants infected with Pseudomonas aeruginosa were available. The risk of bias for the included study was deemed to be low. The quality of the evidence was moderate for the only outcome providing data solely for individuals with infection due to Pseudomonas aeruginosa. For other outcomes, we were unable to judge the quality of the evidence as no data were available for the relevant subset of participants.

Authors' conclusions: The current evidence, limited to one study, shows that there is insufficient evidence to determine effect of choosing antibiotics based on combination antimicrobial susceptibility testing compared to choosing antibiotics based on conventional antimicrobial susceptibility testing in the treatment of acute pulmonary exacerbations in people with cystic fibrosis with chronic Pseudomonas aeruginosa infection. A large international and multicentre study is needed to further investigate this issue. The only study included in the review was published in 2005, and we have not identified any further relevant studies up to March 2017. We therefore do not plan to update this review until new studies are published.

PubMed Disclaimer

Conflict of interest statement

SS: none known.

FR: I have acted as a consultant to Novartis, Roche, Vertex, Boehringer Ingelheim, Bayer, Genentech. I have been paid for lectures by Genentech. I have also received grants as PI for an early intervention study targeting Pseudomonas sponsored by Novartis and as PI for other grants sponsored by Vertex. While I have received grants from Vertex, they do not produce antibiotics that would be eligible for consideration in this review.

TR: none known.

VW: declares grant funding from Cystic Fibrosis Foundation, Cystic Fibrosis Canada, Canadian Institutes of Health Research and Gilead Sciences.

Figures

1
1
Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
See this image and copyright information in PMC

Update of

Similar articles

See all similar articles

Cited by

References

References to studies included in this review

Aaron 2005 {published and unpublished data}
    1. Aaron S, Vandemheen K, Ferris W, Tullis E, Haase D, Berthiaume Y, et al. Treatment of CF exacerbations based on multiple combination antibiotic susceptibility testing-a randomized, double-blind, controlled clinical trial. Pediatric Pulmonology 2005;40(Suppl 28):304. [CFGD REGISTER: PI198a] - PubMed
    1. Aaron S. Clinical evidence for combination antibiotic susceptibility testing (synergy testing). Pediatric Pulmonology 2008;43(Suppl 31):157. [CFGD REGISTER: PI198c]
    1. Aaron SD, Vandemheen KL, Ferris W, Fergusson D, Tullis E, Haase D, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366(9484):463-71. [CFGD REGISTER: PI198b] - PubMed

References to studies excluded from this review

Moskowitz 2011 {published data only}
    1. Moskowitz SM, Emerson JC, McNamara S, Shell RD, Orenstein DM, Rosenbluth D, et al. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection. Pediatric Pulmonology 2011;46(2):184-92. [CFGD REGISTER: PI245] - PMC - PubMed
Oermann 2013 {published data only}
    1. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R, McKevitt M, Montgomery B. Antibiotic susceptibility in Pseudomonas Aeruginosa (PA) isolates following repeated exposure to aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis. Pediatric Pulmonology 2009;44(Suppl 32):309. [ABSTRACT NO.: 278]
    1. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson R, McKevitt M, Montgomery B. Effect of repeated exposure to aztreonam for inhalation solution (AZLI) therapy on cystic fibrosis respiratory pathogens. Pediatric Pulmonology 2009;8(Suppl 2):335. [ABSTRACT NO.: 353]
    1. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Montgomery AB. Effect of multiple courses of Aztreonam Lysine for inhalation (AZLI) on FEV1 and weight in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA): analysis of 18 month data from CP-AI-006. Journal of Cystic Fibrosis 2009;8(Suppl 2):S28. [ABSTRACT NO.: 107]
    1. Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, Quittner AL, Montgomery AB. Adherence over multiple courses of Aztreonam for inhalation (AZLI): effect on disease-related endpoints in patients with cystic fibrosis (CF) and Pseudomonas aeruginosa (PA). Journal of Cystic Fibrosis 2009;8(Suppl 2):S28. [ABSTRACT NO.: 109]
    1. Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatric Pulmonology 2010;45(11):1121-34. 5500100000003719 - PMC - PubMed
Wainwright 2011 {published data only}
    1. Wainwright C, Nakamura C, Geller D, Montgomery AB. A double-blind, multinational, randomized, placebo-controlled trial evaluating aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis (CF), mild lung disease and P. aeruginosa. Journal of Cystic Fibrosis 2010;9(Suppl 1):S22. [ABSTRACT NO.: 81] [CFGD REGISTER: PI243a] - PubMed
    1. Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. Journal of Cystic Fibrosis 2011;10(4):234-42. [CFGD REGISTER: PI243b] - PubMed
Yau 2015 {published data only}
    1. Ratjen F, Stanojevic S, Sonneveld N, Grasemann H, Yau Y, Tullis E, et al. Predictors of response to antibiotic treatment of pulmonary exacerbations in cystic fibrosis patients. Pediatric Pulmonology 2014;49 Suppl 38:355. [ABSTRACT NO.: 384] [CENTRAL: 1012525] [CFGD REGISTER: PI244c]
    1. Waters V, Ratjen F, Tullis E, Corey M, Matukas L, Leahy R, et al. Randomized double blind controlled trial of the use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy in chronic pseudomonas aeruginosa infected cystic fibrosis patients. Pediatric Pulmonology 2010;45 Suppl 33:339. [ABSTRACT NO.: 311] [CENTRAL: 848814] [CFGD REGISTER: PI244a]
    1. Waters V, Yau Y. Use of a biofilm antimicrobial susceptibility assay to guide antibiotic therapy. //clinicaltrials.gov/show/NCT00786513 2015. [CENTRAL: 1050336] [CFGD REGISTER: PI244g]
    1. Waters VJ, Ratjen F, Tullis E, Wilcox PG, Freitag A, Chilvers M, et al. Randomized controlled trial of biofilm antimicrobial susceptibility testing in pulmonary exacerbations in cystic fibrosis patients with chronic pseudomonas aeruginosa infection [abstract]. Pediatric Pulmonology 2014;49 Suppl 38:319, Abstract no: 287. [CFGD REGISTER: PI244b]
    1. Waters VJ, Stanojevic S, Sonneveld N, Klingel M, Grasemann H, Yau YC, et al. Factors associated with response to treatment of pulmonary exacerbations in cystic fibrosis patients. Journal of Cystic Fibrosis 2015;14(6):755-62. [CFGD REGISTER: PI244h] [PMID: ] - PubMed

Additional references

Aaron 2000
    1. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. American Journal of Respiratory and Critical Care Medicine 2000;161(4 Pt 1):1206-12. - PubMed
Burns 2001
    1. Burns JL, Gibson RL, McNamara S, Yim D, Emerson J, Rosenfeld M, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. Journal of Infectious Diseases 2001;183(3):444-52. - PubMed
Ceri 1999
    1. Ceri H, Olson ME, Stremick C, Read RR, Morck D, Buret A. The Calgary Biofilm Device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. Journal of Clinical Microbiology 1999;37(6):1771-6. - PMC - PubMed
Donner 2001
    1. Donner A, Piaggio G, Villar J. Statistical methods for the meta-analysis of cluster randomized trials. Statistical Methods in Medical Research 2001;10(5):325-38. - PubMed
Drenkard 2002
    1. Drenkard E, Ausubel FM. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature 2002;416(6882):740-3. - PubMed
Equi 2002
    1. Equi A, Balfour-Lynn IM, Bush A and Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002;360:978-84. - PubMed
Farrell 2018
    1. Farrell P, Férec C, Macek M, Frischer T, Renner S, Riss K, et al. Estimating the age of p.(Phe508del) with family studies of geographically distinct European populations and the early spread of cystic fibrosis. European Journal of Human Genetics 2018;2018(12):1832-9. [DOI: 10.1038/s41431-018-0234-z] - DOI - PMC - PubMed
Foweraker 2005
    1. Foweraker JE, Laughton CR, Brown DF, Bilton D. Phenotypic variability of Pseudomonas aeruginosa in sputa from patients with acute infective exacerbation of cystic fibrosis and its impact on the validity of antimicrobial susceptibility testing. Journal of Antimicrobial Chemotherapy 2005;55(6):921-7. - PubMed
Gaillard 1995
    1. Gaillard JL, Cahen P, Delacourt C, Silly C, Le Bourgeois M, Coustère C, et al. Correlation between activity of beta-lactam agents in vitro and bacteriological outcome in acute pulmonary exacerbations of cystic fibrosis. European Journal of Clinical Microbiology & Infectious Diseases: official publication of the European Society of Clinical Microbiology 1995;14(4):291-6. - PubMed
Gibson 2003
    1. Gibson RL, Burns JL and Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. American Journal of Respiratory and Critical Care Medicine 2003;168(8):918-51. - PubMed
Henry 1992
    1. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatric Pulmonology 1992;12(3):158-61. - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Jüni 2001
    1. Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6. - PMC - PubMed
Kosorok 2001
    1. Kosorok MR, Zeng L, West SE, Rock MJ, Splaingard ML, Laxova A, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatric Pulmonology 2001;32(4):277-87. - PubMed
Lee 2003
    1. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. Journal of Cystic Fibrosis 2003;2(1):29-34. - PubMed
Moskowitz 2004
    1. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. Journal of Clinical Microbiology 2004;42(5):1915-22. - PMC - PubMed
Moskowitz 2005
    1. Moskowitz SM, Foster JM, Emerson JC, Gibson RL, Burns JL. Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection. Journal of Antimicrobial Chemotherapy 2005;56(5):879-86. - PubMed
Pamukcu 1995
    1. Pamukcu A, Bush A, Buchdahl R. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatric Pulmonology 1995;19(1):10-5. - PubMed
Parmar 1998
    1. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34. - PubMed
Prince 2002
    1. Prince AS. Biofilms, antimicrobial resistance, and airway infection. The New England Journal of Medicine 2002;347(14):1110-1. - PubMed
Regelmann 1990
    1. Regelmann WE, Elliott GR, Warwick WJ and Clawson CC. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. American Review of Respiratory Disease 1990;141(4 Pt 1):914-21. - PubMed
Rosenfeld 2001
    1. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, et al. Defining a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 2001;139(3):359-65. - PubMed
Saiman 1996
    1. Saiman L, Mehar F, Niu WW, Neu HC, Shaw KJ, Miller G, Prince A. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1996;23(3):532-7. - PubMed
Saiman 2003
    1. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56. - PubMed
Singh 2000
    1. Singh PK, Schaefer AL, Parsek MR, Moninger TO, Welsh MJ, Greenberg EP. Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms. Nature 2000;407(6805):762-4. - PubMed
Smith 1999
    1. Smith AL, Doershuk C, Goldman D, Gore E, Hilman B, Marks M, et al. Comparison of a B-lactam alone versus B-lactam and an aminoglycoside for a pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics 1999;134(4):413-21. - PubMed
Smith 2003
    1. Smith AL, Fiel SB, Mayer-Hamblett N, Ramsey B, Burns JL. Susceptibility testing of Pseudomonas aeruginosa isolates and clinical response to parenteral antibiotic administration: lack of association in cystic fibrosis. Chest 2003;123(5):1495-502. - PubMed

References to other published versions of this review

Waters 2008
    1. Waters V, Ratjen F. Antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 3, Issue 2008. Art. No: CD006961. [DOI: 10.1002/14651858.CD006961] - DOI - PubMed
Waters 2015
    1. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No: CD006961. [DOI: 10.1002/14651858.CD006961.pub3] - DOI - PubMed
Waters 2017
    1. Waters V, Ratjen F. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 6. Art. No: CD006961. [DOI: 10.1002/14651858.CD006961.pub4] - DOI - PMC - PubMed

Publication types

MeSH terms

Substances